Participants receiving tralokinumab had a response rate of up to 70% for EASI-50 and up to 40% for EASI-75. In addition, early improvements were observed in ...

Mar 6, 2024 ... The FDA has approved only two biologics to treat atopic dermatitis: dupilumab and tralokinumab. Both are a type of biologic called a monoclonal ...

Dupixent (dupilumab) is the first biologic medication approved by the FDA for adults with moderate to severe atopic dermatitis.

Jan 19, 2023 ... GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

Apr 5, 2021 ... Over 25 new biologics are in development for treatment of atopic dermatitis, including the monoclonal antibody treatments Tralokinumab, ...

Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for the treatment of atopic dermatitis (AD) in addition to biologics.

The U.S. Food and Drug Administration approval of dupilumab for moderate-to-severe atopic dermatitis shifted the paradigm from use of broad, ...

Key words · Atopic dermatitis · eczema · biologics · dupilumab · lebrikizumab · tralokinumab · IL-4 · IL-13 ...

Dupilumab is the only biologic therapy FDA-approved for the treatment of moderate-to-severe AD in patients 6 years and older, with consistent long-term ...

Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions that significantly impair ...